TriSalus Life Sciences Inc. (NASDAQ:TLSI) is gearing up for its quarterly earnings release, with a focus on its innovative approach to oncology treatment.Here are three key insights from the upcoming financial announcement and recent company activities:- Wall Street anticipates an earnings per share (EPS) of -$0.17 and projected revenue of approximately$11.76 million.- Despite a negative price-to-earnings (P/E) ratio of -4.67, TLSI is actively engaging in investor relations events, including the Canaccord ...